Press release
Glioblastoma Clinical Trials Update and Drugs Analysis: EMA, PDMA, FDA Approvals, Medication, Therapies, NDA, IND, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Glioblastoma Clinical Trials
As per DelveInsight's assessment, globally, Glioblastoma pipeline constitutes 190+ key companies continuously working towards developing 200+ Glioblastoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyses DelveInsight.
Request for Sample Report, here @ https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Glioblastoma Pipeline Report:
• Glioblastoma Companies across the globe are diligently working toward developing novel Glioblastoma treatment therapies with a considerable amount of success over the years.
• Glioblastoma companies working in the treatment market are Candel Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Sanofi, Merck Sharp & Dohme LLC, Oblato, Inc.,GlaxoSmithKline, NuvOx Pharma, Biohaven Pharmaceuticals, Vigeo Therapeutics, TVAX Biomedical, Denovo Biopharma, Accendatech, Apollomics, IN8bio, Genenta Science, Sapience Therapeutics, VBI Vaccines, Karyopharm Therapeutics, Novartis, Grupo Español de Investigación en Neurooncología, Plus Therapeutics, Turning Point Therapeutics, Neonc Technologies, and others, are developing therapies for the Glioblastoma treatment
• Emerging Glioblastoma therapies in the different phases of clinical trials are Enzastaurin, Marizomib, Nivolumab, MBM-02, VT1021, Temozolomide, ADI-PEG20, ONC201 and others are expected to have a significant impact on the Glioblastoma market in the coming years.
• In December 2024, Kazia Therapeutics was informed by the FDA that accelerated approval for its brain cancer drug, paxalisib, is unlikely. The FDA stated that the Phase II/III GBM-AGILE study's overall survival data, showing a 3.8-month improvement in glioblastoma patients, does not meet the criteria for accelerated approval.
• On October 15, 2024, the FDA granted Fast Track designation to LP-184, a small-molecule alkylating agent developed by Lantern Pharma for the treatment of glioblastoma (GBM). LP-184 induces tumor cell death through DNA damage and is currently in a Phase 1a trial assessing its safety and tolerability in patients with various solid tumors, including GBM. The Fast Track status aims to accelerate the development and review of LP-184, particularly given the limited treatment options for aggressive brain cancers like GBM.
Glioblastoma Overview
Glioblastoma (GBM) is the most aggressive and common malignant primary brain tumor in adults, classified as a Grade IV glioma by the World Health Organization (WHO). It originates from astrocytes, the star-shaped glial cells in the brain, and is characterized by rapid growth, extensive infiltration into surrounding brain tissue, and resistance to standard therapies. GBM is highly heterogeneous, with a complex genetic and molecular landscape, including alterations in EGFR, PTEN, and TP53.
Symptoms of glioblastoma depend on tumor location and may include headaches, seizures, cognitive impairment, personality changes, and neurological deficits. Diagnosis is typically confirmed through magnetic resonance imaging (MRI) and biopsy. Standard treatment includes maximal safe surgical resection, followed by radiation therapy and chemotherapy with temozolomide. Despite aggressive treatment, GBM has a poor prognosis, with a median survival of approximately 12-15 months.
Recent advancements in research focus on targeted therapies, immunotherapy, tumor-treating fields (TTF), and gene therapy to improve patient outcomes. However, the blood-brain barrier and tumor heterogeneity pose significant challenges in drug delivery and treatment efficacy. Due to its aggressive nature and high recurrence rate, glioblastoma remains a major area of investigation in neuro-oncology.
Get a Free Sample PDF Report to know more about Glioblastoma Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Glioblastoma Drugs Under Different Phases of Clinical Development Include:
• Enzastaurin: Denovo BioPharma
• Marizomib: Bristol-Myers Squibb
• VT1021: Vigeo Therapeutics
• ONC201: Chimerix, Inc.
• And others.
Route of Administration
Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Know more about Glioblastoma pipeline Analysis @ https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Molecule Type
Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Glioblastoma Pipeline Therapeutics Assessment
• Glioblastoma Assessment by Product Type
• Glioblastoma By Stage and Product Type
• Glioblastoma Assessment by Route of Administration
• Glioblastoma By Stage and Route of Administration
• Glioblastoma Assessment by Molecule Type
• Glioblastoma by Stage and Molecule Type
DelveInsight's Glioblastoma Pipeline Report covers around 190+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Glioblastoma product details are provided in the report. Download the Glioblastoma pipeline report to learn more about the emerging Glioblastoma therapies at: https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key companies in the Glioblastoma Therapeutics Market include:
Key Glioblastoma companies developing therapies are Candel Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Sanofi, Merck Sharp & Dohme LLC, Oblato, Inc.,GlaxoSmithKline, NuvOx Pharma, Biohaven Pharmaceuticals, Vigeo Therapeutics, TVAX Biomedical, Denovo Biopharma, Accendatech, Apollomics, IN8bio, Genenta Science, Sapience Therapeutics, VBI Vaccines, Karyopharm Therapeutics, Novartis, Grupo Español de Investigación en Neurooncología, Plus Therapeutics, Turning Point Therapeutics, Neonc Technologies, and others.
Glioblastoma Pipeline Analysis:
The Glioblastoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Glioblastoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Treatment.
• Glioblastoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioblastoma market.
Download Sample PDF Report to know more about Glioblastoma drugs and therapies- https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Glioblastoma Pipeline Market Drivers
The glioblastoma pipeline market, a highly aggressive brain tumor, is driven by several factors. Firstly, the high unmet medical need and limited treatment options for glioblastoma create a strong demand for innovative therapies. The increasing incidence of glioblastoma cases globally contributes to the market growth. Additionally, advancements in technology and understanding of the molecular basis of the disease have led to the discovery of potential targets for therapeutic intervention. Collaboration between pharmaceutical companies, academic institutions, and research organizations has facilitated the development of novel treatment approaches. Lastly, regulatory incentives and fast-track designations by regulatory authorities have expedited the development and approval process for glioblastoma therapies.
Glioblastoma Pipeline Market Barriers
The glioblastoma pipeline market faces several barriers that impact its development and growth. Firstly, the complexity and heterogeneity of glioblastoma tumors pose significant challenges in identifying effective therapeutic targets and developing targeted therapies. The blood-brain barrier also limits the delivery of drugs to the tumor site, reducing their effectiveness. Glioblastoma's aggressive nature and rapid progression make it difficult to conduct clinical trials and evaluate the long-term efficacy of potential treatments. Moreover, the high cost of research and development, coupled with the uncertain reimbursement landscape, may deter pharmaceutical companies from investing in glioblastoma therapies. Regulatory requirements and stringent approval processes also add to the challenges in bringing new treatments to market. Lastly, limited patient enrollment in clinical trials and the scarcity of reliable biomarkers further complicate the development of innovative therapies for glioblastoma.
Scope of Glioblastoma Pipeline Drug Insight
• Coverage: Global
• Key Glioblastoma Companies: Candel Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Sanofi, Merck Sharp & Dohme LLC, Oblato, Inc.,GlaxoSmithKline, NuvOx Pharma, Biohaven Pharmaceuticals, Vigeo Therapeutics, TVAX Biomedical, Denovo Biopharma, Accendatech, Apollomics, IN8bio, Genenta Science, Sapience Therapeutics, VBI Vaccines, Karyopharm Therapeutics, Novartis, Grupo Español de Investigación en Neurooncología, Plus Therapeutics, Turning Point Therapeutics, Neonc Technologies, and others.
• Key Glioblastoma Therapies: Enzastaurin, Marizomib, VT1021, ONC201 and others.
• Glioblastoma Therapeutic Assessment: Glioblastoma current marketed and Glioblastoma emerging therapies
• Glioblastoma Market Dynamics: Glioblastoma market drivers and Glioblastoma market barriers
Request for Sample PDF Report for Glioblastoma Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Glioblastoma Report Introduction
2. Glioblastoma Executive Summary
3. Glioblastoma Overview
4. Glioblastoma- Analytical Perspective In-depth Commercial Assessment
5. Glioblastoma Pipeline Therapeutics
6. Glioblastoma Late Stage Products (Phase II/III)
7. Glioblastoma Mid Stage Products (Phase II)
8. Glioblastoma Early Stage Products (Phase I)
9. Glioblastoma Preclinical Stage Products
10. Glioblastoma Therapeutics Assessment
11. Glioblastoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Glioblastoma Key Companies
14. Glioblastoma Key Products
15. Glioblastoma Unmet Needs
16 . Glioblastoma Market Drivers and Barriers
17. Glioblastoma Future Perspectives and Conclusion
18. Glioblastoma Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market-forecast
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Xerostomia Market: https://www.delveinsight.com/whitepaper-newsletter/xerostomia-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/osteoarthritis-market
• Brain/cranial Implants Market: https://www.delveinsight.com/report-store/brain-implants-market-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Pharma Competitive Intelligence: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Surgical Site Infections Market: https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiac Resynchronization Therapy Device Market: https://www.delveinsight.com/report-store/cardiac-resynchronization-therapy-market
• Central Retinal Venous Occulsion Market: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
• Cerebral Vein Thrombosis Market: https://www.delveinsight.com/report-store/cerebral-vein-thrombosis-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Febrile Neutropenia Market: https://www.delveinsight.com/report-store/febrile-neutropenia-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage
Case study: https://www.delveinsight.com/case-study/go-to-market-strategy
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioblastoma Clinical Trials Update and Drugs Analysis: EMA, PDMA, FDA Approvals, Medication, Therapies, NDA, IND, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight here
News-ID: 3865935 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Glioblastoma
Key Trends Shaping the Future Glioblastoma Multiforme Market From 2025-2034: Adv …
Which drivers are expected to have the greatest impact on the over the glioblastoma multiforme market's growth?
The growing number of brain disorder cases is anticipated to boost the glioblastoma multiforme market in the coming years. A brain disorder is a condition that affects the brain's structure or function, leading to cognitive, emotional, or physical difficulties. The rise in brain disorder cases is attributed to factors such as an aging population,…
Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Glioblastoma Pipeline Insight, 2024," report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioblastoma Pipeline Report
* DelveInsight's Glioblastoma pipeline report depicts…
Glioblastoma Multiforme Market Insights, Forecast to 2031
"Glioblastoma Multiforme Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Glioblastoma Multiforme market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Glioblastoma Multiforme industry, providing stakeholders with a nuanced perspective on market…
Beyond Bravery - Bill Fitzpatrick's Fight Against Glioblastoma
Bill Fitzpatrick Jr, a retired sales professional from GE, has recently ventured into the world of writing with his debut book. Inspired by his experiences during taking care of his wife, who had Glioblastoma, Bill felt the need to share his journey and provide support to other families navigating similar challenges. In this article, we will dive into Bill's background, his motivation for becoming an author, details about his latest…
Recurrent Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Recurrent Glioblastoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Recurrent Glioblastoma Pipeline Report
DelveInsight's Recurrent Glioblastoma…
Revolutionizing Glioblastoma Treatment Strategies: A Deep Dive into the Glioblas …
The Glioblastoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Glioblastoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Glioblastoma pipeline landscape and fostering the potential growth of Glioblastoma therapeutic advancements.
Key Takeaways from the Glioblastoma Pipeline Report
• DelveInsight's Glioblastoma pipeline report depicts a robust space with 195+ active players…
